ArticleCase reports in oncology
Case Report: Rapid Improvement of Chronic Lymphocytic Leukemia Infiltration of the Scalp by BCL2-Inhibitor.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic lymphocytic leukemia (CLL) is a malignancy of mature CD5+ B-lymphocytes. While it typically involves the peripheral blood, bone marrow, lymph nodes, and spleen, cutaneous infiltration - leukemia cutis - is a rare manifestation of the disease, causing aesthetic problem to the patients. Case Presentation: A 60-year-old man with a 2-year history of CLL presented with a scalp plaque. Biopsy confirmed leukemic skin infiltration. The patient was started on obinutuzumab and venetoclax. Following an infusion reaction, venetoclax monotherapy was continued, leading to rapid improvement. Conclusion: Cutaneous infiltrates in CLL patients are a rare manifestation with unclear prognostic significance, typically occurring after diagnosis, as in our case. New therapies for CLL, such as BCL2 inhibitors, not only offer more effective disease control but also appear to help manage associated cutaneous infiltrates, as in our patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.